GET DAILY SIGNALSProgyny (PGNY) Rises +32.8% Following Record Third Quarter and Selling Season
Key Takeaways
- Progyny (PGNY) shares climbed roughly 32.8% over the last 30 days, rising from about $25.91 on October 6, 2026, to around $34.40, touching a fresh 52-week high in the process.
- The catalyst was a record third quarter and, more importantly, the strongest selling season in the company's history, headlined by 1.3 million new covered lives.
- Management raised the midpoint of its full-year 2026 revenue and adjusted EBITDA guidance, reinforcing confidence in sustained demand for fertility and family-building benefits.
- Over the trailing quarter, the stock has followed a choppier path, falling sharply in early August after Q2 guidance commentary before steadily recovering and then surging.
- Analyst price targets currently range from about $30 to $38, with a consensus rating of Buy and an average target near $34, reflecting an extended but well-supported rally.
- For additional detail on valuation and earnings expectations, explore Progyny's Price Targets, Earnings, and Forecast pages.
Company Overview and Market Position
Progyny, Inc. (Nasdaq: PGNY) is a leading benefits management company focused on fertility, family building, and women's health solutions. The company serves large self-insured employers, health plans, and benefit purchasers, helping them manage the clinical, pharmacy, and financial complexity of fertility and related care. Its proprietary Smart Cycle model bundles the services needed for a full course of treatment, complemented by the integrated Progyny Rx pharmacy program and dedicated Progyny Care Advocates.
Progyny has expanded well beyond fertility into pregnancy and postpartum care, menopause and midlife health, and parent and child well-being. With near-universal client retention, a disciplined cost-management track record, and a scalable care-management platform, the company occupies a differentiated position in employer-sponsored benefits. Investors follow the stock closely because covered lives and client retention translate directly into recurring, multi-year revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Progyny shares advanced approximately 32.8%, climbing from a closing price of $25.91 on October 6, 2026, to about $34.40. The bulk of that move arrived after third-quarter results and a record selling-season update were reported on November 4, 2026, when the stock jumped roughly 14% in a single session and touched a 52-week high of $35.50.
The trailing quarter tells a broader story. Starting near $31.37 in early August, the stock sold off sharply after second-quarter earnings commentary flagged softer near-term guidance and summer seasonality, sliding into the low-to-mid $20s by mid-August. It then staged a steady recovery through September and October, returning to the $30 area before the November earnings surge pushed it to roughly $34.40, a net quarterly gain of about 9.7% with considerable volatility along the way.
What Drove the Recent 30-Day Move
The primary driver was the company's third-quarter 2026 report, released November 4, 2026. Progyny delivered record revenue of approximately $341.25 million, up nearly 9% year over year, along with non-GAAP earnings of $0.52 per share, which edged past consensus estimates. Net income rose to $26.25 million from $13.86 million in the prior-year period.
The larger catalyst, however, was forward-looking. Management disclosed its most successful selling season ever, adding a record 1.3 million new covered lives and more than 85 new clients for the 2027 plan year while retaining near 100% of its existing book. New accounts spanned prestigious universities, a major technology leader, a top U.S. bank, and the nation's largest public-employee health benefit fund. Because covered lives generate recurring revenue, the intake significantly improved visibility into 2027 growth, prompting the sharp re-rating.
Progyny also raised the midpoint of its full-year 2026 guidance, now projecting revenue of $1.365 billion to $1.385 billion and adjusted EBITDA of $235 million to $240 million. The combination of in-line quarterly results, a record pipeline, and raised guidance outweighed near-term margin pressure and competitive dynamics, driving the stock to a 52-week high. From what I see, this level of visibility is what sets the stage for sustained momentum.
Performance Over the Trailing Quarter
The quarter's broader trend was shaped by two contrasting earnings events. In early August, Progyny reported strong second-quarter results—revenue of $350.5 million and adjusted EPS of $0.55—yet shares fell sharply as investors focused on conservative third-quarter guidance and a more pronounced summer slowdown. The company trimmed its full-year revenue midpoint slightly, and the stock declined from the low-$30s into the mid-$20s.
That sell-off set the stage for the subsequent recovery. Through September and October, shares gradually rebuilt as sentiment improved on resilient employer demand and healthy member engagement. The November third-quarter report then reversed the narrative entirely, as the record selling season demonstrated that demand remained robust and that the earlier slowdown was seasonal rather than structural. Over the full three-month span, the stock moved from about $31.37 to roughly $34.40, recovering all its August losses and more.
Key Factors to Watch Next
Several factors will shape Progyny's trajectory from here. The primary focus is execution of the newly signed 2027 client cohort, particularly whether the 1.3 million new covered lives go live on schedule—many are expected to launch in early 2027, with a meaningful portion arriving midyear. Utilization trends, including slightly lower expected utilization for a large public-sector client, will also influence revenue per member.
Investors should monitor full-year 2027 guidance, which management said it will provide with year-end results in February 2027. Additional watch items include medical cost inflation, competitive pressure in fertility benefits, the ramp of the Progyny Select fully insured offering for smaller employers, and continued share-repurchase activity. Fourth-quarter 2026 guidance calls for revenue of $344.7 million to $364.7 million, representing growth of 8.3% to 14.6%, offering a near-term benchmark for the stock's current valuation. I’m watching this closely as the new covered lives begin to contribute.
AI Tools for Tracking Market Trends
One resource I turn to for additional perspective on automated strategies across the market is Tickeron’s AI Trading Bots. The platform offers a range of data-driven approaches that can complement fundamental research on names like PGNY, helping to highlight patterns or positioning that might otherwise go unnoticed in a fast-moving sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PGNY's RSI Indicator ascending out of oversold territory
The RSI Indicator for PGNY moved out of oversold territory on September 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 40 of the 42 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on PGNY as a result. In 73 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for PGNY just turned positive on October 07, 2026. Looking at past instances where PGNY's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
PGNY moved above its 50-day moving average on October 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PGNY crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +3.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where PGNY advanced for three days, in 231 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 160 of 214 cases where PGNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
PGNY broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating fairly steady price growth. PGNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 53 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PGNY's P/B Ratio (5.818) is slightly higher than the industry average of (3.512). P/E Ratio (35.802) is within average values for comparable stocks, (126.100). PGNY's Projected Growth (PEG Ratio) (0.090) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. PGNY's P/S Ratio (1.816) is very high in comparison to the industry average of (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools
Industry ManagedHealthCare
Advertisement